UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 10, 2020

Fortive Corporation

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation)

001-37654
(Commission File Number)

6920 Seaway Blvd
Everett, WA
98203
(Address of principal executive offices)

(425) 446-5000
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisi	S:
	/ritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	oliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	re-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	re-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securi	es registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbols	Name of each exchange on which registered
Common stock, par value \$0.01 per share	FTV	New York Stock Exchange
5% Mandatory convertible preferred stock, Series A, par value \$0.01 per share	FTV. PRA	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

			ì
f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying	ng with any new	or	
evised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \square			

Emerging growth company \square

Item 2.02 Results of Operations and Financial Condition

On November 9, 2020, Fortive Corporation (the "Company") issued a press release announcing that the Company will participate in a publicly webcast presentation at the Baird 2020 Global Industrial Conference (the "Baird Conference") on November 11, 2020 during which the Company may discuss, among other matters, recast historical financial information reflecting both the separation of Vontier Corporation on October 9, 2020 (the "Separation") and the management of the Company in three reporting segments effective as of September 26, 2020 (the "Segmentation"). In advance of the Company's presentation at the Baird Conference, the Company will post on its website recast historical financial information reflecting the Separation and the Segmentation (the "Recast Historical Financial Information"). A copy of the Recast Historical Financial Information is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information set forth in this Item 2.02 of this Current Report on Form 8-K and the Recast Historical Financial Information attached hereto as Exhibit 99.1 are being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits:

Exhibit No.	Description
99.1	Recast Historical Financial Information
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FORTIVE CORPORATION

Date: November 10, 2020 By: /s/ Daniel B. Kim

Daniel B. Kim

Vice President - Associate General Counsel and Secretary

FORTIVE CORPORATION AND SUBSIDIARIES SUPPLEMENTAL SEGMENT INFORMATION

On October 9, 2020, Fortive Corporation ("Fortive" or the "Company") completed the separation (the "Separation") of its Industrial Technologies segment through the spin-off of Vontier Corporation ("Vontier"), as effectuated through the distribution of 80.1% of the outstanding shares of Vontier common stock as a dividend to Fortive shareholders as of September 25, 2020, with Fortive retaining 19.9% of the outstanding Vontier common stock immediately following the Separation.

In light of the Separation, Fortive changed its internal reporting structure on the first day of the fourth quarter, September 26, 2020, to reflect organizational and leadership changes that allow the Company to better assess the operational performance of and allocate resources to its businesses. Fortive's chief operating decision maker assesses performance and allocates resources based on its new operating segments, which are also its new reportable segments. Below is a description of Fortive's new reportable segments:

Reportable Segment	Operating Company
Intelligent Operating Solutions	Fluke
	Industrial Scientific, including Intelex
	Accruent
	Gordian
Precision Technologies	Tektronix
	Pacific Scientific Energetic Materials Company
	Qualitrol
	Andersen-Negele
	Gems
	Setra
	Hengstler and Dynapar
Advanced Healthcare Solutions	Advanced Sterilization Products
	Fluke Health Solutions
	Censis
	Invetech

The Company will begin reporting its results under its new reportable segments and reporting Vontier as discontinued operations beginning with the Annual Report on Form 10-K for the year ending December 31, 2020.

Fortive is providing the below unaudited supplemental financial data of the Company for the fiscal years ended December 31, 2018 and December 31, 2019 and the fiscal quarters ended March 29, 2019, June 28, 2019, September 27, 2019, December 31, 2019, March 27, 2020, June 26, 2020, and September 25, 2020 to assist investors in assessing Fortive's historical performance on the basis of the Company's new reportable segments. Results for Total Fortive in the unaudited supplemental financial data set forth herein are based on continuing operations only.

SUPPLEMENTAL SEGMENT INFORMATION REVENUE BY SEGMENT (\$ in millions) (unaudited)

	(Intelligent Operating Solutions	Precision Technologies	Advanced Healthcare Solutions	Corporate	Total Fortive
Revenue (GAAP)						
Year Ended December 31, 2018	\$	1,576.3	\$ 1,901.4	\$ 322.7	\$ 	\$ 3,800.4
Quarter Ended March 29, 2019	\$	453.9	\$ 448.4	\$ 78.1	\$ _	\$ 980.4
Quarter Ended June 28, 2019		459.0	466.3	244.1	_	1,169.4
Quarter Ended September 27, 2019		458.2	440.1	252.5	_	1,150.8
Quarter Ended December 31, 2019		527.8	453.6	281.9	_	1,263.3
Year Ended December 31, 2019	\$	1,898.9	\$ 1,808.4	\$ 856.6	\$ _	\$ 4,563.9
Quarter Ended March 27, 2020	\$	466.7	\$ 391.3	\$ 250.1	\$ _	\$ 1,108.1
Quarter Ended June 26, 2020		413.0	377.3	251.3	_	1,041.6
Quarter Ended September 25, 2020		459.1	418.5	282.2	_	1,159.8

SUPPLEMENTAL SEGMENT INFORMATION OPERATING PROFIT AND ADJUSTED OPERATING PROFIT BY SEGMENT SUMMARY*

(\$ in millions) (unaudited)

	Intelligent Operating Solutions	Precision Technologies	Advanced Healthcare Solutions		Corporate		Total Fortive
Operating Profit (GAAP)		J			 •		
Year Ended December 31, 2018	\$ 350.3	\$ 381.5	\$	5.3	\$ (91.8)	\$	645.3
Quarter Ended March 29, 2019	\$ 79.7	\$ 73.2	\$	(16.7)	\$ (24.2)	\$	112.0
Quarter Ended June 28, 2019	82.9	92.4		(54.3)	(25.4)		95.6
Quarter Ended September 27, 2019	52.2	79.8		(13.0)	(22.6)		96.4
Quarter Ended December 31, 2019	74.2	79.2		12.0	(25.5)		139.9
Year Ended December 31, 2019	\$ 289.0	\$ 324.6	\$	(72.0)	\$ (97.7)	\$	443.9
Quarter Ended March 27, 2020	\$ 81.1	\$ 73.5	\$	(15.8)	\$ (23.4)	\$	115.4
Quarter Ended June 26, 2020	54.4	77.1		(1.9)	(27.1)		102.5
Quarter Ended September 25, 2020	77.5	82.1		1.8	(23.8)		137.6
Adjusted Operating Profit (non-GAAP)*							
Year Ended December 31, 2018	\$ 468.4	\$ 404.3	\$	70.6	\$ (91.8)	\$	851.5
Quarter Ended March 29, 2019	\$ 131.0	\$ 80.0	\$	14.5	\$ (24.2)	\$	201.3
Quarter Ended June 28, 2019	127.3	100.0		53.3	(25.4)		255.2
Quarter Ended September 27, 2019	108.6	85.4		58.0	(22.6)		229.4
Quarter Ended December 31, 2019	136.4	103.1		68.9	(25.5)		282.9
Year Ended December 31, 2019	\$ 503.3	\$ 368.5	\$	194.7	\$ (97.7)	\$	968.8
Quarter Ended March 27, 2020	\$ 124.4	\$ 78.0	\$	49.3	\$ (23.4)	\$	228.3
Quarter Ended June 26, 2020	95.4	81.4		58.2	(27.1)		207.9
Quarter Ended September 25, 2020	115.2	86.4		54.3	(23.8)		232.1
,					. ,		

^{*} Reconciliation of GAAP to Non-GAAP financial measures are set forth in the following pages.

FORTIVE CORPORATION AND SUBSIDIARIES RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES AND OTHER INFORMATION

Adjusted Operating Profit and Adjusted Operating Profit Margin

We disclose the non-GAAP measures of historical adjusted operating profit and historical adjusted operating profit margin which, to the extent applicable, make the following adjustments to corresponding GAAP operating profit and GAAP operating profit margin:

- Excluding on a pretax basis amortization of acquisition-related intangible assets;
- Excluding on a pretax basis acquisition and other transaction costs deemed significant ("Transaction Costs");
- Excluding on a pretax basis the effect of deferred revenue and inventory fair value adjustments related to significant acquisitions; and
- Excluding on a pretax basis discrete restructuring charges

Acquisition and Divestiture Related Items

While we have a history of acquisition and divestiture activity, we do not acquire and divest of businesses and assets on a predictable cycle. The amount of an acquisition's purchase price allocated to intangible assets and related amortization term and the deferred revenue and inventory fair value adjustments are unique to each acquisition and can vary significantly from acquisition to acquisition. In addition, the Transaction Costs and non-recurring gain on disposition of assets are unique to each transaction, are impacted from period to period depending on the number of acquisitions or divestitures evaluated, pending or completed during such period, and the complexity of such transactions. We adjust for, and identify as significant, Transaction Costs, acquisition related fair value adjustments to deferred revenue and inventory, and corresponding restructuring charges primarily related to acquisitions, in each case, incurred in a given period, if we determine that such costs and adjustments exceed the range of our typical transaction costs and adjustments, respectively, in a given period. We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation and that intangible assets and deferred revenue and inventory fair value adjustments related to past acquisitions will recur in future periods until such intangible assets and deferred revenue and inventory fair value adjustments, as applicable, have been fully amortized.

Discrete Restructuring Costs

We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Fortive Business System. Because these restructuring plans are incremental to the fundamental activities that arise in the ordinary course of our business and we believe are not indicative of our ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.

Management believes that these non-GAAP financial measures provide useful information to investors by reflecting additional ways of viewing aspects of our operations that, when reconciled to the corresponding GAAP measure, help our investors to understand the long-term profitability trends of our business, and facilitate comparisons of our operational performance and profitability to prior and future periods and to our peers.

These non-GAAP measures should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measures, and may not be comparable to similarly titled measures reported by other companies.

(\$ in millions) (unaudited)

For the Year Ended December 31, 2018

		Intelligent Operating Solutions	Precision Technologies		Advanced Healthcare Solutions		Corporate	Total Fortive
Revenue (GAAP)	\$	1,576.3	\$ 1,901.4	\$	322.7	\$	_	\$ 3,800.4
Adjusted Operating Profit								
Operating Profit (GAAP)	\$	350.3	\$ 381.5	\$	5.3	\$	(91.8)	\$ 645.3
Acquisition-Related Transaction Costs		24.9	0.4		42.0		_	67.3
Acquisition-Related Fair Value Adjustment to Deferred Revenue and Inventory	S	34.4	_		_		_	34.4
Amortization of Acquisition-Related Intangible Assets		58.8	22.4		23.3		_	104.5
Adjusted Operating Profit (Non-GAAP)	\$	468.4	\$ 404.3	\$	70.6	\$	(91.8)	\$ 851.5
Adjusted Operating Profit Margin (a)								
Operating Profit (GAAP) Margin		22.2 %	20.1 %	D	1.6 %	,		17.0 %
Acquisition-Related Transaction Costs		1.6 %	— %	ó	13.1 %)		1.8 %
Acquisition-Related Fair Value Adjustment to Deferred Revenue and Inventory	S	1.6 %	— %	ó	— %)		0.7 %
Amortization of Acquisition-Related Intangible Assets		3.7 %	1.2 %	ó	7.2 %)		2.7 %
Adjusted Operating Profit Margin (Non-GAAP)		29.1 %	21.3 %	D	21.9 %	•		22.2 %

⁽a) The adjusted operating profit margin reflects the corresponding adjustment to GAAP revenue of \$34.4 million in acquisition-related fair value adjustments to deferred revenue for both Intelligent Operating Solutions and Total Fortive.

(\$ in millions) (unaudited)

For the Three Months Ended March 29, 2019

	For the Three Wighths Ended Watch 25, 2017											
		Intelligent Operating Solutions		Precision Technologies			Advanced Healthcare Solutions		Corporate		Total Fortive	
Revenue (GAAP)	\$	453.9	\$	448.4		\$	78.1	\$	_	\$	980.4	
Adjusted Operating Profit												
Operating Profit (GAAP)	\$	79.7	\$	73.2		\$	(16.7)	\$	(24.2)	\$	112.0	
Acquisition-Related Transaction Costs		2.7		1.3			25.5		_		29.5	
Acquisition-Related Fair Value Adjustment to Deferred Revenue and Inventory	S	15.7		_			_		_		15.7	
Amortization of Acquisition-Related Intangible Assets		32.9		5.5			5.7		_		44.1	
Adjusted Operating Profit (Non-GAAP)	\$	131.0	\$	80.0		\$	14.5	\$	(24.2)	\$	201.3	
Adjusted Operating Profit Margin (a)												
Operating Profit (GAAP) Margin		17.6 %	6	16.3	%		(21.4) %				11.4 %	
Acquisition-Related Transaction Costs		0.6 %	%	0.3	%		32.7 %				3.0 %	
Acquisition-Related Fair Value Adjustment to Deferred Revenue and Inventory	S	2.5 %	%	_	%		_ %				1.3 %	
Amortization of Acquisition-Related Intangible Assets		7.2 %	%	1.2	%		7.3 %				4.5 %	
Adjusted Operating Profit Margin (Non-GAAP)		27.9 %	6	17.8	%		18.6 %				20.2 %	

⁽a) The adjusted operating profit margin reflects the corresponding adjustment to GAAP revenue of \$15.7 million in acquisition-related fair value adjustments to deferred revenue for both Intelligent Operating Solutions and Total Fortive.

(\$ in millions) (unaudited)

For the Three Months Ended June 28, 2019

	1 of the Times Months Ended Guile 20, 2017											
		Intelligent Operating Solutions		Precision Technologies		Advanced Healthcare Solutions		Corporate		Total Fortive		
Revenue (GAAP)	\$	459.0	\$	466.3	\$	244.1	\$	_	\$	1,169.4		
Adjusted Operating Profit												
Operating Profit (GAAP)	\$	82.9	\$	92.4	\$	(54.3)	\$	(25.4)	\$	95.6		
Acquisition-Related Transaction Costs		3.4		2.4		25.5		_		31.3		
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory		7.2		_		51.8		_		59.0		
Amortization of Acquisition-Related Intangible Assets		33.8		5.2		30.3		_		69.3		
Adjusted Operating Profit (Non-GAAP)	\$	127.3	\$	100.0	\$	53.3	\$	(25.4)	\$	255.2		
Adjusted Operating Profit Margin (a)												
Operating Profit (GAAP) Margin		18.1 %	o	19.8	%	(22.2)	%			8.2 %		
Acquisition-Related Transaction Costs		0.7 %	6	0.5	%	10.4	%			2.7 %		
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory		1.1 %	6	_	%	21.0	%			4.8 %		
Amortization of Acquisition-Related Intangible Assets		7.4 %	6	1.1	%	12.4	%			5.9 %		
Adjusted Operating Profit Margin (Non-GAAP)		27.3 %	6	21.4	%	21.6	%			21.6 %		

⁽a) The adjusted operating profit margin reflects the corresponding adjustments to GAAP revenue in acquisition-related fair value adjustments to deferred revenue of \$7.2 million for Intelligent Operating Solutions, \$2.8 million for Advanced Healthcare Solutions, and \$10.0 million for Total Fortive.

(\$ in millions) (unaudited)

For the Three Months Ended September 27, 2019

	Tot the Three Months Ended September 27, 2017											
		Intelligent Operating Solutions		Precision Technologies			Advanced Healthcare Solutions		Corporate		Total Fortive	
Revenue (GAAP)	\$	458.2	\$	440.1	\$	5	252.5	\$	_	\$	1,150.8	
Adjusted Operating Profit												
Operating Profit (GAAP)	\$	52.2	\$	79.8	\$	5	(13.0)	\$	(22.6)	\$	96.4	
Acquisition-Related Transaction Costs		2.0		0.7			20.9		_		23.6	
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory		15.2		_			20.3		_		35.5	
Amortization of Acquisition-Related Intangible Assets		39.2		4.9			29.8		_		73.9	
Adjusted Operating Profit (Non-GAAP)	\$	108.6	\$	85.4	\$	5	58.0	\$	(22.6)	\$	229.4	
Adjusted Operating Profit Margin (a)												
Operating Profit (GAAP) Margin		11.4 %		18.1	%		(5.1) %				8.4 %	
Acquisition-Related Transaction Costs		0.4 %		0.2	%		8.3 %				2.1 %	
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory		2.5 %		_	%		7.7 %				2.7 %	
Amortization of Acquisition-Related Intangible Assets		8.6 %		1.1	%		11.8 %				6.4 %	
Adjusted Operating Profit Margin (Non-GAAP)		22.9 %		19.4	%		22.7 %				19.6 %	

⁽a) The adjusted operating profit margin reflects the corresponding adjustments to GAAP revenue in acquisition-related fair value adjustments to deferred revenue of \$15.2 million for Intelligent Operating Solutions, \$2.8 million for Advanced Healthcare Solutions, and \$18.0 million for Total Fortive.

(\$ in millions) (unaudited)

For the Three Months Ended December 31, 2019

	For the Three Months Ended December 31, 2019											
		Intelligent Operating Solutions			Precision Technologies			Advanced Healthcare Solutions			Corporate	Total Fortive
Revenue (GAAP)	\$	527.8		\$	453.6		\$	281.9		\$	_	\$ 1,263.3
Adjusted Operating Profit												
Operating Profit (GAAP)	\$	74.2		\$	79.2		\$	12.0		\$	(25.5)	\$ 139.9
Acquisition-Related Transaction Costs		3.9			(0.4)			22.6			_	26.1
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory	S	9.6			_			1.2			_	10.8
Amortization of Acquisition-Related Intangible Assets		35.8			4.8			33.1			_	73.7
Restructuring		12.9			19.5			_			_	32.4
Adjusted Operating Profit (Non-GAAP)	\$	136.4		\$	103.1		\$	68.9		\$	(25.5)	\$ 282.9
Adjusted Operating Profit Margin (a)												
Operating Profit (GAAP) Margin		14.1	%		17.5	%		4.3	%			11.1 %
Acquisition-Related Transaction Costs		0.7	%		(0.1)	%		8.0	%			2.1 %
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory	S	1.4	%		_	%		0.2	%			0.6 %
Amortization of Acquisition-Related Intangible Assets		6.8	%		1.1	%		11.7	%			5.8 %
Restructuring		2.4	%		4.2	%		_	%			2.6 %
Adjusted Operating Profit Margin (Non-GAAP)		25.4	%		22.7	%		24.2	%			22.2 %

⁽a) The adjusted operating profit margin reflects the corresponding adjustments to GAAP revenue in acquisition-related fair value adjustments to deferred revenue of \$8.5 million for Intelligent Operating Solutions, \$2.3 million for Advanced Healthcare Solutions, and \$10.8 million for Total Fortive.

(\$ in millions) (unaudited)

For the Year Ended December 31, 2019

	To the Teat Ended December 51, 2017									
		Intelligent Operating Solutions		Precision Technologies			Advanced Healthcare Solutions		Corporate	Total Fortive
Revenue (GAAP)	\$	1,898.9	\$	1,808.4		\$	856.6	\$	_	\$ 4,563.9
Adjusted Operating Profit										
Operating Profit (GAAP)	\$	289.0	\$	324.6		\$	(72.0)	\$	(97.7)	\$ 443.9
Acquisition-Related Transaction Costs		12.0		4.0			94.5		_	110.5
Acquisition-Related Fair Value Adjustment to Deferred Revenue and Inventory	S	47.7		_			73.3		_	121.0
Amortization of Acquisition-Related Intangible Assets		141.7		20.4			98.9		_	261.0
Restructuring		12.9		19.5			_			32.4
Adjusted Operating Profit (Non-GAAP)	\$	503.3	\$	368.5		\$	194.7	\$	(97.7)	\$ 968.8
Adjusted Operating Profit Margin (a)										
Operating Profit (GAAP) Margin		15.2 %		17.9	%		(8.4) %	6		9.7 %
Acquisition-Related Transaction Costs		0.6 %		0.2	%		11.0	%		2.4 %
Acquisition-Related Fair Value Adjustment to Deferred Revenue and Inventory	S	1.9 %		_	%		8.4	%		2.5 %
Amortization of Acquisition-Related Intangible Assets		7.5 %		1.2	%		11.5	%		5.7 %
Restructuring		0.7 %		1.1	%		_ 9	%		0.7 %
Adjusted Operating Profit Margin (Non-GAAP)		25.9 %		20.4	%		22.5 %	6		21.0 %

⁽a) The adjusted operating profit margin reflects the corresponding adjustments to GAAP revenue in acquisition-related fair value adjustments to deferred revenue of \$46.6 million for Intelligent Operating Solutions, \$7.9 million for Advanced Healthcare Solutions, and \$54.5 million for Total Fortive.

(\$ in millions) (unaudited)

For the Three Months Ended March 27, 2020

	Tot the Three Months Ended March 27, 2020										
		Intelligent Operating Solutions		Precision Technologies			Advanced Healthcare Solutions		Corporate		Total Fortive
Revenue (GAAP)	\$	466.7	\$	391.3	\$	3	250.1	\$	_	\$	1,108.1
Adjusted Operating Profit											
Operating Profit (GAAP)	\$	81.1	\$	73.5	\$	3	(15.8)	\$	(23.4)	\$	115.4
Acquisition-Related Transaction Costs		0.3		_			20.4		_		20.7
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory		4.9		_			9.1		_		14.0
Amortization of Acquisition-Related Intangible Assets		38.1		4.5			35.6		_		78.2
Adjusted Operating Profit (Non-GAAP)	\$	124.4	\$	78.0	\$;	49.3	\$	(23.4)	\$	228.3
Adjusted Operating Profit Margin (a)											
Operating Profit (GAAP) Margin		17.4 %		18.8	%		(6.3) %				10.4 %
Acquisition-Related Transaction Costs		0.1 %		_	%		8.2 %				1.9 %
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory		0.7 %		_	%		3.4 %				1.1 %
Amortization of Acquisition-Related Intangible Assets		8.2 %		1.1	%		14.2 %				7.1 %
Adjusted Operating Profit Margin (Non-GAAP)		26.4 %		19.9	%		19.5 %				20.5 %

⁽a) The adjusted operating profit margin reflects the corresponding adjustments to GAAP revenue in acquisition-related fair value adjustments to deferred revenue of \$4.6 million for Intelligent Operating Solutions, \$2.3 million for Advanced Healthcare Solutions, and \$6.9 million for Total Fortive.

(\$ in millions) (unaudited)

For the Three Months Ended June 26, 2020

	Intelligent Operating Solutions		Precision Technologies		Advanced Healthcare Solutions		Corporate	Total Fortive
Revenue (GAAP)	\$ 413.0	\$	377.3		\$ 251.3	\$	_	\$ 1,041.6
Adjusted Operating Profit								
Operating Profit (GAAP)	\$ 54.4	\$	77.1		\$ (1.9)	\$	(27.1)	\$ 102.5
Acquisition-Related Transaction Costs	0.3		_		22.0		_	22.3
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory	3.0		_		2.7		_	5.7
Amortization of Acquisition-Related Intangible Assets	37.7		4.3		35.4		_	77.4
Adjusted Operating Profit (Non-GAAP)	\$ 95.4	\$	81.4		\$ 58.2	\$	(27.1)	\$ 207.9
Adjusted Operating Profit Margin (a)								
Operating Profit (GAAP) Margin	13.2 %)	20.4	%	(0.8)	%		9.8 %
Acquisition-Related Transaction Costs	0.1 %	ó	_	%	8.8	%		2.1 %
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory	0.5 %	ó	_	%	0.9	%		0.6 %
Amortization of Acquisition-Related Intangible Assets	9.1 %	ó	1.2	%	14.1	%		7.4 %
Adjusted Operating Profit Margin (Non-GAAP)	22.9 %	•	21.6	%	23.0	%		19.9 %

⁽a) The adjusted operating profit margin reflects the corresponding adjustments to GAAP revenue in acquisition-related fair value adjustments to deferred revenue of \$3.0 million for Intelligent Operating Solutions, \$1.6 million for Advanced Healthcare Solutions, and \$4.6 million for Total Fortive.

(\$ in millions) (unaudited)

For the Three Months Ended September 25, 2020

	Intelligent Operating Solutions		Precision Technologies		Advanced Healthcare Solutions		Corporate	Total Fortive
Revenue (GAAP)	\$ 459.1	\$	418.5		\$ 282.2	\$	_	\$ 1,159.8
Adjusted Operating Profit								
Operating Profit (GAAP)	\$ 77.5	\$	82.1		\$ 1.8	\$	(23.8)	\$ 137.6
Acquisition-Related Transaction Costs	0.2		0.1		14.0		_	14.3
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory	(0.1)		_		3.2		_	3.1
Amortization of Acquisition-Related Intangible Assets	 37.6		4.2		35.3		_	 77.1
Adjusted Operating Profit (Non-GAAP)	\$ 115.2	\$	86.4		\$ 54.3	\$	(23.8)	\$ 232.1
Adjusted Operating Profit Margin (a)								
Operating Profit (GAAP) Margin	16.9 %	,	19.6	%	0.6	%		11.9 %
Acquisition-Related Transaction Costs	— %)	_	%	5.0	%		1.2 %
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory	— %))	_	%	1.1	%		0.3 %
Amortization of Acquisition-Related Intangible Assets	8.2 %)	1.0	%	12.5	%		6.6 %
Adjusted Operating Profit Margin (Non-GAAP)	25.1 %	•	20.6	%	19.2	%		20.0 %

⁽a) The adjusted operating profit margin reflects the corresponding adjustment to GAAP revenue of \$0.8 million in acquisition-related fair value adjustments to deferred revenue for both Advanced Healthcare Solutions and Total Fortive.